Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Ritodrine
- Accession Number
- DB00867 (APRD00541)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Adrenergic beta-agonist used to control premature labor. [PubChem]
- Structure
Structure for DB00867 (Ritodrine)
- Synonyms
- DU-21220
- Ritodrina
- Ritodrine
- Ritodrinium
- Product Ingredients
Ingredient UNII CAS InChI Key Ritodrine Hydrochloride ESJ56Q60GC 23239-51-2 IDLSITKDRVDKRV-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Yutopar Inj 50mg/5ml Liquid 10 mg Intravenous Bristol Labs Division Of Bristol Myers Squibb 1984-12-31 2001-07-30 Canada 
Yutopar Tab 10mg Tablet 10 mg Oral Bristol Labs Division Of Bristol Myers Squibb 1984-12-31 2001-07-30 Canada - International/Other Brands
- Yutopar
- Categories
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Alcohols
- Amines
- Amino Alcohols
- Autonomic Agents
- Beta2 Agonists
- Ethylamines
- Genito Urinary System and Sex Hormones
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Phenethylamines
- Propanolamines
- Propanols
- Reproductive Control Agents
- Sympathomimetics
- Sympathomimetics, Labour Repressants
- Tocolytic Agents
- UNII
- I0Q6O6740J
- CAS number
- 26652-09-5
- Weight
- Average: 287.3535
Monoisotopic: 287.152143543 - Chemical Formula
- C17H21NO3
- InChI Key
- IOVGROKTTNBUGK-SJCJKPOMSA-N
- InChI
- InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1
- IUPAC Name
- 4-(2-{[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)phenol
- SMILES
- C[[email protected]](NCCC1=CC=C(O)C=C1)[[email protected]](O)C1=CC=C(O)C=C1
Pharmacology
- Indication
For the treatment and prophylaxis of premature labour
- Structured Indications
- Not Available
- Pharmacodynamics
Beta-2 adrenergic receptors are located at sympathetic neuroeffector junctions of many organs, including uterus. Ritodrine is beta-2 adrenergic agonist. It stimulates beta-2 adrenergic receptor, increases cAMP level and decreases intracellular calcium concentration. The decrease of calcium concentration leads to a relaxation of uterine smooth muscle and, therefore, a decrease in premature uterine contractions.
- Mechanism of action
Ritodrine is beta-2 adrenergic agonist. It binds to beta-2 adrenergic receptors on outer membrane of myometrial cell, activates adenyl cyclase to increase the level of cAMP which decreases intracellular calcium and leads to a decrease of uterine contractions.
Target Actions Organism ABeta-2 adrenergic receptor agonistHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
~56%
- Metabolism
Hepatic, by both the mother and fetus
- Route of elimination
- Not Available
- Half life
1.7-2.6 hours
- Clearance
- Not Available
- Toxicity
LD50=64mg/kg (mice, IV); LD50=540 mg/kg (mice, oral); LD50=85 mg/kg (rat, IV)
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Ritodrine. Experimental Acebutolol The risk or severity of adverse effects can be increased when Ritodrine is combined with Acebutolol. Approved, Investigational Alfuzosin Alfuzosin may decrease the vasoconstricting activities of Ritodrine. Approved, Investigational Alprenolol Alprenolol may decrease the bronchodilatory activities of Ritodrine. Approved, Withdrawn Amineptine The risk or severity of adverse effects can be increased when Amineptine is combined with Ritodrine. Illicit, Withdrawn Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ritodrine. Approved Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Ritodrine. Approved Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Ritodrine. Approved, Illicit, Investigational Atenolol Atenolol may decrease the bronchodilatory activities of Ritodrine. Approved Atomoxetine Atomoxetine may increase the hypertensive activities of Ritodrine. Approved Atosiban The risk or severity of adverse effects can be increased when Ritodrine is combined with Atosiban. Approved, Investigational Azosemide Ritodrine may increase the hypokalemic activities of Azosemide. Investigational Bendroflumethiazide Ritodrine may increase the hypokalemic activities of Bendroflumethiazide. Approved Benmoxin The risk or severity of adverse effects can be increased when Benmoxin is combined with Ritodrine. Withdrawn Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Ritodrine. Approved, Illicit Benzylpenicilloyl Polylysine Ritodrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Betahistine The therapeutic efficacy of Ritodrine can be decreased when used in combination with Betahistine. Approved, Investigational Betaxolol Betaxolol may decrease the bronchodilatory activities of Ritodrine. Approved, Investigational Bisoprolol Bisoprolol may decrease the bronchodilatory activities of Ritodrine. Approved Bopindolol Bopindolol may decrease the bronchodilatory activities of Ritodrine. Approved Brofaromine The risk or severity of adverse effects can be increased when Brofaromine is combined with Ritodrine. Experimental Bromocriptine Bromocriptine may increase the hypertensive and vasoconstricting activities of Ritodrine. Approved, Investigational Bucindolol The risk or severity of adverse effects can be increased when Ritodrine is combined with Bucindolol. Investigational Bumetanide Ritodrine may increase the hypokalemic activities of Bumetanide. Approved Bunazosin Bunazosin may decrease the vasoconstricting activities of Ritodrine. Investigational Bupranolol Bupranolol may decrease the bronchodilatory activities of Ritodrine. Approved Cabergoline Cabergoline may increase the hypertensive and vasoconstricting activities of Ritodrine. Approved Caroxazone The risk or severity of adverse effects can be increased when Caroxazone is combined with Ritodrine. Withdrawn Carteolol Carteolol may decrease the bronchodilatory activities of Ritodrine. Approved Carvedilol Carvedilol may decrease the vasoconstricting activities of Ritodrine. Approved, Investigational Celiprolol The risk or severity of adverse effects can be increased when Ritodrine is combined with Celiprolol. Approved, Investigational Chlorothiazide Ritodrine may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Chlorphentermine The risk or severity of adverse effects can be increased when Ritodrine is combined with Chlorphentermine. Illicit, Withdrawn Chlorthalidone Ritodrine may increase the hypokalemic activities of Chlorthalidone. Approved Clenbuterol The risk or severity of adverse effects can be increased when Ritodrine is combined with Clenbuterol. Approved, Investigational, Vet Approved Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Ritodrine. Approved, Investigational, Vet Approved Cloranolol Cloranolol may decrease the bronchodilatory activities of Ritodrine. Experimental Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ritodrine. Approved Cyclopenthiazide Ritodrine may increase the hypokalemic activities of Cyclopenthiazide. Experimental Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Ritodrine. Approved, Investigational Desvenlafaxine Desvenlafaxine may increase the tachycardic activities of Ritodrine. Approved, Investigational Dibenzepin The risk or severity of adverse effects can be increased when Dibenzepin is combined with Ritodrine. Experimental Dihydroergotamine Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Ritodrine. Approved, Investigational Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Ritodrine. Approved Dopamine The risk or severity of adverse effects can be increased when Ritodrine is combined with Dopamine. Approved Dosulepin The risk or severity of adverse effects can be increased when Dosulepin is combined with Ritodrine. Approved Doxazosin Doxazosin may decrease the vasoconstricting activities of Ritodrine. Approved Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Ritodrine. Approved, Investigational Doxofylline The risk or severity of adverse effects can be increased when Doxofylline is combined with Ritodrine. Approved, Investigational Dronabinol Dronabinol may increase the tachycardic activities of Ritodrine. Approved, Illicit Duloxetine Duloxetine may increase the tachycardic activities of Ritodrine. Approved Epanolol The risk or severity of adverse effects can be increased when Ritodrine is combined with Epanolol. Experimental Ephedrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Ephedrine. Approved Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Ritodrine. Approved, Vet Approved Epitizide Ritodrine may increase the hypokalemic activities of Epitizide. Experimental Ergoloid mesylate Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Ritodrine. Approved Ergonovine Ergonovine may increase the hypertensive and vasoconstricting activities of Ritodrine. Approved Ergotamine Ergotamine may increase the hypertensive and vasoconstricting activities of Ritodrine. Approved Esmirtazapine The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Ritodrine. Investigational Esmolol Esmolol may decrease the bronchodilatory activities of Ritodrine. Approved Etacrynic acid Ritodrine may increase the hypokalemic activities of Etacrynic acid. Approved, Investigational Etilefrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Etilefrine. Withdrawn Fenoterol The risk or severity of adverse effects can be increased when Ritodrine is combined with Fenoterol. Approved, Investigational Fenozolone The risk or severity of adverse effects can be increased when Ritodrine is combined with Fenozolone. Experimental Furazolidone The risk or severity of adverse effects can be increased when Furazolidone is combined with Ritodrine. Approved, Investigational, Vet Approved Furosemide Ritodrine may increase the hypokalemic activities of Furosemide. Approved, Vet Approved Harmaline The risk or severity of adverse effects can be increased when Harmaline is combined with Ritodrine. Experimental Hydracarbazine The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Ritodrine. Experimental Hydrochlorothiazide Ritodrine may increase the hypokalemic activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Ritodrine may increase the hypokalemic activities of Hydroflumethiazide. Approved, Investigational Hydroxyamphetamine The risk or severity of adverse effects can be increased when Ritodrine is combined with Hydroxyamphetamine. Approved Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Ritodrine. Approved Indapamide Ritodrine may increase the hypokalemic activities of Indapamide. Approved Indoramin Indoramin may decrease the vasoconstricting activities of Ritodrine. Withdrawn Iobenguane The therapeutic efficacy of Iobenguane can be decreased when used in combination with Ritodrine. Approved, Investigational Iprindole The risk or severity of adverse effects can be increased when Iprindole is combined with Ritodrine. Experimental Iproclozide The risk or severity of adverse effects can be increased when Iproclozide is combined with Ritodrine. Withdrawn Iproniazid The risk or severity of adverse effects can be increased when Iproniazid is combined with Ritodrine. Withdrawn Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ritodrine. Approved Isoprenaline The risk or severity of adverse effects can be increased when Ritodrine is combined with Isoprenaline. Approved, Investigational Isoxsuprine The risk or severity of adverse effects can be increased when Ritodrine is combined with Isoxsuprine. Approved, Withdrawn Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Ritodrine. Approved Levomilnacipran Levomilnacipran may increase the tachycardic activities of Ritodrine. Approved, Investigational Linezolid Linezolid may increase the hypertensive activities of Ritodrine. Approved, Investigational Lofepramine The risk or severity of adverse effects can be increased when Lofepramine is combined with Ritodrine. Experimental Mebanazine The risk or severity of adverse effects can be increased when Mebanazine is combined with Ritodrine. Withdrawn Mefenorex The risk or severity of adverse effects can be increased when Ritodrine is combined with Mefenorex. Experimental Mephentermine The risk or severity of adverse effects can be increased when Ritodrine is combined with Mephentermine. Approved Mepindolol Mepindolol may decrease the bronchodilatory activities of Ritodrine. Experimental Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Ritodrine. Approved, Investigational Methamphetamine The risk or severity of adverse effects can be increased when Ritodrine is combined with Methamphetamine. Approved, Illicit Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Ritodrine. Approved, Investigational Methyclothiazide Ritodrine may increase the hypokalemic activities of Methyclothiazide. Approved Methylene blue The risk or severity of adverse effects can be increased when Methylene blue is combined with Ritodrine. Approved, Investigational Methylergometrine Methylergometrine may increase the hypertensive and vasoconstricting activities of Ritodrine. Approved Metolazone Ritodrine may increase the hypokalemic activities of Metolazone. Approved Metoprolol Metoprolol may decrease the bronchodilatory activities of Ritodrine. Approved, Investigational Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Ritodrine. Approved Milnacipran Milnacipran may increase the tachycardic activities of Ritodrine. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Minaprine is combined with Ritodrine. Approved Mirtazapine The risk or severity of adverse effects can be increased when Mirtazapine is combined with Ritodrine. Approved Moclobemide The risk or severity of adverse effects can be increased when Moclobemide is combined with Ritodrine. Approved, Investigational Nabilone Nabilone may increase the tachycardic activities of Ritodrine. Approved, Investigational Nebivolol Nebivolol may decrease the bronchodilatory activities of Ritodrine. Approved, Investigational Nialamide The risk or severity of adverse effects can be increased when Nialamide is combined with Ritodrine. Withdrawn Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Ritodrine. Approved Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Ritodrine. Approved Nylidrin The risk or severity of adverse effects can be increased when Ritodrine is combined with Nylidrin. Approved Octamoxin The risk or severity of adverse effects can be increased when Octamoxin is combined with Ritodrine. Withdrawn Opipramol The risk or severity of adverse effects can be increased when Opipramol is combined with Ritodrine. Investigational Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Ritodrine. Approved Oxprenolol Oxprenolol may decrease the bronchodilatory activities of Ritodrine. Approved Oxymetazoline The risk or severity of adverse effects can be increased when Ritodrine is combined with Oxymetazoline. Approved, Investigational Pargyline The risk or severity of adverse effects can be increased when Pargyline is combined with Ritodrine. Approved Penbutolol Penbutolol may decrease the bronchodilatory activities of Ritodrine. Approved, Investigational Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Ritodrine. Approved Pheniprazine The risk or severity of adverse effects can be increased when Pheniprazine is combined with Ritodrine. Withdrawn Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Ritodrine. Approved, Illicit Phenoxypropazine The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Ritodrine. Withdrawn Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Ritodrine. Approved, Illicit Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Ritodrine. Approved Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Ritodrine. Approved, Vet Approved, Withdrawn Piretanide Ritodrine may increase the hypokalemic activities of Piretanide. Approved Pirlindole The risk or severity of adverse effects can be increased when Pirlindole is combined with Ritodrine. Approved Pivhydrazine The risk or severity of adverse effects can be increased when Pivhydrazine is combined with Ritodrine. Withdrawn Polythiazide Ritodrine may increase the hypokalemic activities of Polythiazide. Approved Prazosin Prazosin may decrease the vasoconstricting activities of Ritodrine. Approved Prenalterol The risk or severity of adverse effects can be increased when Ritodrine is combined with Prenalterol. Experimental Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Ritodrine. Approved, Investigational Procaterol The risk or severity of adverse effects can be increased when Ritodrine is combined with Procaterol. Approved, Investigational Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Ritodrine. Approved Pseudoephedrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Pseudoephedrine. Approved Quinethazone Ritodrine may increase the hypokalemic activities of Quinethazone. Approved Racepinephrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Racepinephrine. Approved Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Ritodrine. Approved Safrazine The risk or severity of adverse effects can be increased when Safrazine is combined with Ritodrine. Withdrawn Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Ritodrine. Approved, Investigational, Vet Approved Silodosin Silodosin may decrease the vasoconstricting activities of Ritodrine. Approved Spironolactone Spironolactone may decrease the vasoconstricting activities of Ritodrine. Approved Synephrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Synephrine. Experimental Tamsulosin Tamsulosin may decrease the vasoconstricting activities of Ritodrine. Approved, Investigational Tedizolid Phosphate Tedizolid Phosphate may increase the hypertensive activities of Ritodrine. Approved Terazosin Terazosin may decrease the vasoconstricting activities of Ritodrine. Approved Terbutaline The risk or severity of adverse effects can be increased when Ritodrine is combined with Terbutaline. Approved Tertatolol Tertatolol may decrease the bronchodilatory activities of Ritodrine. Experimental Tetryzoline The risk or severity of adverse effects can be increased when Ritodrine is combined with Tetryzoline. Approved Tianeptine The risk or severity of adverse effects can be increased when Tianeptine is combined with Ritodrine. Approved, Investigational Toloxatone The risk or severity of adverse effects can be increased when Toloxatone is combined with Ritodrine. Approved Torasemide Ritodrine may increase the hypokalemic activities of Torasemide. Approved Tramazoline The risk or severity of adverse effects can be increased when Ritodrine is combined with Tramazoline. Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ritodrine. Approved, Investigational Tretoquinol The risk or severity of adverse effects can be increased when Ritodrine is combined with Tretoquinol. Experimental Trichlormethiazide Ritodrine may increase the hypokalemic activities of Trichlormethiazide. Approved, Vet Approved Trimazosin Trimazosin may decrease the vasoconstricting activities of Ritodrine. Experimental Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Ritodrine. Approved Tyramine The risk or severity of adverse effects can be increased when Ritodrine is combined with Tyramine. Investigational, Nutraceutical Urapidil Urapidil may decrease the vasoconstricting activities of Ritodrine. Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ritodrine. Approved Venlafaxine Venlafaxine may increase the tachycardic activities of Ritodrine. Approved - Food Interactions
- Not Available
References
- Synthesis Reference
Naoki Yamazaki, Yoshimasa Fukuda, Yoshiaki Shibazaki, Tetsutarou Niizato, Isao Kosugi, Shin Yoshioka, "(-)-ritodrine, therapeutic compositions and use, and method of preparation." U.S. Patent US5449694, issued July, 1992.
US5449694- General References
- Not Available
- External Links
- ATC Codes
- G02CA01 — Ritodrine
- MSDS
- Download (48 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Healthy Volunteers 1 4 Completed Prevention Premature Births 1 4 Recruiting Prevention Preterm Labor Without Delivery 1 Not Available Recruiting Treatment Premature Labour 1
Pharmacoeconomics
- Manufacturers
- Abraxis pharmaceutical products
- Hospira inc
- Astrazeneca lp
- Packagers
- Solvay Pharmaceuticals
- Dosage forms
Form Route Strength Liquid Intravenous 10 mg Tablet Oral 10 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 88-90 °C Not Available water solubility Complete Not Available logP 2.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.179 mg/mL ALOGPS logP 1.53 ALOGPS logP 1.82 ChemAxon logS -3.2 ALOGPS pKa (Strongest Acidic) 9.15 ChemAxon pKa (Strongest Basic) 9.81 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 72.72 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 83.02 m3·mol-1 ChemAxon Polarizability 31.56 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9871 Blood Brain Barrier - 0.8115 Caco-2 permeable - 0.5546 P-glycoprotein substrate Substrate 0.692 P-glycoprotein inhibitor I Non-inhibitor 0.953 P-glycoprotein inhibitor II Non-inhibitor 0.8732 Renal organic cation transporter Non-inhibitor 0.6134 CYP450 2C9 substrate Non-substrate 0.6367 CYP450 2D6 substrate Substrate 0.5054 CYP450 3A4 substrate Non-substrate 0.5874 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9442 CYP450 2D6 inhibitor Non-inhibitor 0.6034 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8351 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7277 Ames test Non AMES toxic 0.7799 Carcinogenicity Non-carcinogens 0.9177 Biodegradation Not ready biodegradable 0.8862 Rat acute toxicity 2.2303 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7534 hERG inhibition (predictor II) Inhibitor 0.5409
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as phenethylamines. These are compounds containing a phenethylamine moiety, which consists of a phenyl group substituted at the second position by an ethan-1-amine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenethylamines
- Direct Parent
- Phenethylamines
- Alternative Parents
- Phenylpropanes / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- Phenethylamine / Phenylpropane / Phenol / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Secondary alcohol / 1,2-aminoalcohol / Secondary amine / Secondary aliphatic amine / Amine
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- amphetamines (CHEBI:8872)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Protein homodimerization activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
- Gene Name
- ADRB2
- Uniprot ID
- P07550
- Uniprot Name
- Beta-2 adrenergic receptor
- Molecular Weight
- 46458.32 Da
References
- Tanaka N, Tamai T, Mukaiyama H, Hirabayashi A, Muranaka H, Akahane S, Miyata H, Akahane M: Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence. J Med Chem. 2001 Apr 26;44(9):1436-45. [PubMed:11311067]
- Schwarz MK, Page P: Preterm labour: an overview of current and emerging therapeutics. Curr Med Chem. 2003 Aug;10(15):1441-68. [PubMed:12871140]
- Lye SJ, Dayes BA, Freitag CL, Brooks J, Casper RF: Failure of ritodrine to prevent preterm labor in the sheep. Am J Obstet Gynecol. 1992 Nov;167(5):1399-408. [PubMed:1332478]
- Bianchetti A, Manara L: In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol. 1990 Aug;100(4):831-9. [PubMed:1976401]
- Lenselink DR, Kuhlmann RS, Lawrence JM, Kolesari GL: Cardiovascular teratogenicity of terbutaline and ritodrine in the chick embryo. Am J Obstet Gynecol. 1994 Aug;171(2):501-6. [PubMed:8059831]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Phosphogluconate dehydrogenase (decarboxylating) activity
- Specific Function
- Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
- Gene Name
- PGD
- Uniprot ID
- P52209
- Uniprot Name
- 6-phosphogluconate dehydrogenase, decarboxylating
- Molecular Weight
- 53139.56 Da
References
- Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 05:08